Results 171 to 180 of about 31,381 (233)

A Tale of Two Cell Lines: Characterization of Differential Efficacy of Small Molecule Drugs Cediranib and NU‐7441 on Primary Versus Metastatic Colorectal Cancer

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Colorectal cancer is recognized as one of the leading causes of cancer death amongst both sexes in the U.S. Despite rigorous screening, those diagnosed with colon cancer often face poor prognosis, and approximately 70% of affected patients will develop metastatic relapse. The investigation of colon carcinoma cell lines' genetic variability and
Josephine D. Tsang, Cai M. Roberts
wiley   +1 more source

DIRAS1 Drives Oxaliplatin Resistance in Colorectal Cancer via PHB1-Mediated Mitochondrial Homeostasis. [PDF]

Biology (Basel)
Long M, Ouyang Q, Wen J, Zeng X, Xu Z, Zhong S, Huang C, Luo JL.   +7 more
europepmc   +1 more source

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Hematological malignancies remain one of the leading causes of morbidity and mortality despite advances in targeted therapies, immunotherapy, and stem cell transplantation. Emerging evidence indicates that treatment efficacy and toxicity depend not only on the choice of therapy but also on its timing relative to the patient's internal ...
Andrej Belančić, Marko Skelin, Yun Wah Lam, Almir Fajkić, Bruna Perkov‐Stipičin, Rossana Roncato, Ivan Krečak, Marko Lucijanić   +7 more
wiley   +1 more source

[Ethanol promotes oxaliplatin resistance in colorectal cancer by activating the TGF‑β/Smad/P21 signaling axis]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Tan B, Weng N, Zeng W, Gu J, Weng L, Wen H, Xiao H, Zheng K.   +7 more
europepmc   +1 more source

Research Progress on Reversing Oxaliplatin Resistance in Colon Cancer

Advances in Clinical Medicine, 2023
openaire   +1 more source

DEPP1: A prognostic biomarker linked to stroma‑rich and immunosuppressive microenvironment, promoting oxaliplatin resistance in gastric cancer. [PDF]

Oncol Rep
Qiu X, Pan T, Kuang T, Shen Y, Zheng Y, Geng H, Ni B, Xia X, Zhu C, Zhang Z, Cao H, Tu L.   +11 more
europepmc   +1 more source

Neutrophil‐Macrophage Interactions Shape Inflammatory Macrophage Remodeling in Gastric Cancer During Chemo‐Immunotherapy

Cancer Science, Volume 117, Issue 8, Page 2115-2131, August 2026.
PD‐1 blockade combined with chemotherapy induces MHC‐II+ inflammatory neutrophils in gastric cancer, which engage in dynamic crosstalk with macrophages to remodel the tumor microenvironment toward a pro‐inflammatory state, thereby amplifying antitumor immune responses.
Keita H. Nagaoka, Hiroki Yamashita, Chiaki Mashima, Guoqiang Zhang, Hitoshi Saito, Tatsunori Minamide, Takuya Nakatsuru, Ryo Kamata, Shunsuke A. Sakai, Gaku Yamamoto, Tomoko Y. Morita, Kazuki Nakai, Yumi Hakozaki, Kumi Kinoshita, Yui Takahashi, Izuma Nakayama, Akihito Kawazoe, Sai M. Pulukuri, Yuko Ishii, Hiroshi Haeno, Yukie Kashima, Kohei Shitara, Tomonori Yano, Takeshi Saito, Akihiro Ohashi   +24 more
wiley   +1 more source

Alectinib and SALL4-Targeted Fatty Acid Oxidation: A Strategy to Combat Oxaliplatin Resistance in Gastric Cancer. [PDF]

Turk J Gastroenterol
Xiao Y, Fang K, Liao J, Zhou H, Zhu W, Liu Z, Ouyang H, Liu K.   +7 more
europepmc   +1 more source

Gasdermin‐Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer

Cancer Science, Volume 117, Issue 8, Page 2064-2084, August 2026.
Pyroptosis is a double‐edged sword in colorectal cancer (CRC): chronic low‐grade pyroptosis promotes tumor progression, whereas acute induction of pyroptosis in cancer cells triggers antitumor immunity and enhances therapeutic response. Targeting gasdermin‐mediated pyroptosis represents a promising strategy for CRC treatment.
Kaibo Guo, Yuqian Feng, Jiamin Lu, Nuerbiye Abudurexiti, Xinlei Zhou, Mengfan Wei, Song Zheng   +6 more
wiley   +1 more source

NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer. [PDF]

World J Gastroenterol
Niu YR, Xiang MD, Yang WW, Fang YT, Qian HL, Sun YK.   +5 more
europepmc   +1 more source